Sold as Bidil. Every FDA application for this active ingredient: 1 branded and 2 generic.
As of Nov 16, 2026, FDA lists 3 applications for Hydralazine Hydrochloride; Isosorbide Dinitrate (sold as Bidil), first approved Jun 23, 2005, with 0 new uses approved and 0 published complete response letters.
| Diuretics vs. Afterload Reduction for Treatment of HeartLogic AlertsHeart Failure, Congestive · Heart Center Research, LLC | Phase 4 | Recruiting | Jan 23, 2024 |
| Verification of the Efficacy and Safety of the BAROSTIM NEO System in the Treatment of Drug Resistant HypertensionHigh Blood Pressure · CVRx, Inc. | Not applicable | Active, not recruiting | Nov 16, 2011 |
| Jun 23, 2005 | BidilNDA 20727 · New combination | Azurity | 5 | Marketed |
| Apr 6, 2022 | Isosorbide Dinitrate And Hydralazine HydrochlorideANDA 215586 | Ingenus Pharms LLC | 0 | Marketed |
| Jan 17, 2024 | Isosorbide Dinitrate And Hydralazine HydrochlorideANDA 215988 | Pharmazone | 1 | Marketed |
Applications, approvals and products come from FDA's Drugs@FDA data files, refreshed weekly, grouped by active ingredient as FDA spells it. Complete response letters are FDA's published letters. Medicare spending is CMS's Part D and Part B dashboard, matched to this ingredient by generic name; shortages are FDA's shortage list, matched by application number; clinical trials are ClinicalTrials.gov studies naming the ingredient as an intervention, refreshed daily; safety programs are FDA's REMS list, matched by application number or, for shared programs, by ingredient. Drugs@FDA